Michael A. Pisetsky Sells 3,127 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN - Get Free Report) SVP Michael A. Pisetsky sold 3,127 shares of SiBone stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $18.29, for a total value of $57,192.83. Following the transaction, the senior vice president directly owned 261,681 shares in the company, valued at approximately $4,786,145.49. This trade represents a 1.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

SiBone Stock Up 1.8%

SIBN traded up $0.34 during trading on Thursday, reaching $18.78. 294,940 shares of the stock traded hands, compared to its average volume of 393,604. SiBone has a fifty-two week low of $11.70 and a fifty-two week high of $20.05. The stock's 50-day simple moving average is $18.17 and its two-hundred day simple moving average is $16.29. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.53 and a quick ratio of 7.26. The stock has a market cap of $800.40 million, a price-to-earnings ratio of -29.34 and a beta of 0.93.

SiBone (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.09. The firm had revenue of $47.29 million for the quarter, compared to analyst estimates of $45.13 million. SiBone had a negative return on equity of 16.00% and a negative net margin of 15.03%. As a group, equities research analysts expect that SiBone will post -0.78 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have commented on the company. Truist Financial boosted their target price on SiBone from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 target price on shares of SiBone in a research note on Tuesday, May 6th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $24.00 price target on shares of SiBone in a report on Tuesday, May 6th.

Institutional Trading of SiBone

Several institutional investors and hedge funds have recently made changes to their positions in the business. Proficio Capital Partners LLC bought a new position in SiBone during the 4th quarter worth about $155,000. Charles Schwab Investment Management Inc. raised its position in shares of SiBone by 2.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 321,263 shares of the company's stock valued at $4,504,000 after buying an additional 6,171 shares in the last quarter. Raymond James Financial Inc. bought a new position in SiBone in the fourth quarter valued at approximately $1,233,000. AlphaQuest LLC increased its holdings in shares of SiBone by 13,950.6% during the fourth quarter. AlphaQuest LLC now owns 11,662 shares of the company's stock worth $164,000 after buying an additional 11,579 shares in the last quarter. Finally, Essex Investment Management Co. LLC grew its stake in shares of SiBone by 24.3% in the fourth quarter. Essex Investment Management Co. LLC now owns 208,160 shares of the company's stock worth $2,918,000 after purchasing an additional 40,636 shares during the last quarter. Institutional investors own 98.11% of the company's stock.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.